Anti-CTLA4 Treatment Reduces Lymphedema Risk
Author Information
Author(s): Wolf Stefan, Madanchi Matiar, Turko Patrick, Hollmén Maija, Tugues Sonia, von Atzigen Julia, Giovanoli Pietro, Dummer Reinhard, Lindenblatt Nicole, Halin Cornelia, Detmar Michael, Levesque Mitchell, Gousopoulos Epameinondas
Primary Institution: University Hospital Zurich, University of Zurich
Hypothesis
Can anti-CTLA4 treatment reduce the risk of lymphedema in melanoma patients?
Conclusion
Anti-CTLA4 treatment significantly reduces the risk of lymphedema in melanoma patients and improves lymphatic function in a mouse model.
Supporting Evidence
- Anti-CTLA4 treatment reduced lymphedema risk from 18.8% to 10.5% in treated patients.
- Only 2.9% of patients receiving anti-CTLA4 developed lymphedema compared to higher rates in other treatment groups.
- Mouse models showed significant reduction in edema and improved lymphatic function with anti-CTLA4 treatment.
Takeaway
This study found that a medicine called anti-CTLA4 can help stop swelling in patients who have had cancer surgery.
Methodology
The study involved a retrospective analysis of melanoma patients and a mouse model to assess the effects of anti-CTLA4 treatment on lymphedema.
Potential Biases
Potential biases in retrospective patient data collection.
Limitations
The mouse model may not replicate all features of human lymphedema, and the treatment period was limited for animal welfare reasons.
Participant Demographics
Melanoma patients undergoing lymphadenectomy and adjuvant immunotherapy.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website